This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hui, A.-M. Articles by Fine, H. A. Search for Related Content PubMed PubMed Citation Articles by Hui, A.-M. Articles by Fine, H. A.

Agents with Selective Estrogen Receptor (ER) Modulator Activity Induce Apoptosis In vitro and In vivo in ER-Negative Glioma Cells

¹ Neuro-Oncology Branch, National Cancer Institute, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, and ² Celgene, San Diego, California

Tamoxifen, a member of the selective estrogen receptor modulator (SERM) family, is widely used in the treatment of estrogen receptor (ER)-expressing breast cancer. It has previously been shown that high-dose tamoxifen has cytotoxic activity against glioma cells, but whether this effect is drug specific or represents a general property of SERMs is unknown. In this study, we demonstrate that tamoxifen and CC-8490, a novel benzopyranone with SERM activity, induce glioma cell apoptosis in a dose- and time-dependent manner. Moreover, administration of tamoxifen and CC-8490 suppresses tumor growth in vivo and extends animal survival in glioma xenograft models. None of the eight glioma cell lines examined express either ER- or -ß, suggesting the mechanism for tamoxifen– and CC-8490–induced glioma cell apoptosis is independent of the ER signaling pathway. Complementary DNA microarray expression profiling allowed us to identify a subset of genes specifically regulated by tamoxifen and CC-8490, and not by other apoptotic stimuli, including nuclear factor (NF)-B with its target genes IEX-3, SOD2, IL6, and IL8. We demonstrate that suppression of NF-B activation markedly enhances SERM-induced apoptosis, suggesting a role for NF-B in protecting glioma cells from SERM-induced cytotoxicity. These findings demonstrate for the first time that a SERM other than tamoxifen can induce glioma cell apoptosis in vitro and in vivo and that the clinical efficacy of SERMs for the treatment of malignant gliomas could potentially be enhanced by simultaneous inhibition of the NF-B pathway.

This article has been cited by other articles:

				S. Kotliarova, S. Pastorino, L. C. Kovell, Y. Kotliarov, H. Song, W. Zhang, R. Bailey, D. Maric, J. C. Zenklusen, J. Lee, et al. Glycogen Synthase Kinase-3 Inhibition Induces Glioma Cell Death through c-MYC, Nuclear Factor-{kappa}B, and Glucose Regulation Cancer Res., August 15, 2008; 68(16): 6643 - 6651. [Abstract] [Full Text] [PDF]

				F. Wu, D. Grossenbacher, and H. Gehring New transition state-based inhibitor for human ornithine decarboxylase inhibits growth of tumor cells Mol. Cancer Ther., June 1, 2007; 6(6): 1831 - 1839. [Abstract] [Full Text] [PDF]

				S. Olivier, P. Close, E. Castermans, L. de Leval, S. Tabruyn, A. Chariot, M. Malaise, M.-P. Merville, V. Bours, and N. Franchimont Raloxifene-Induced Myeloma Cell Apoptosis: A Study of Nuclear Factor-{kappa}B Inhibition and Gene Expression Signature Mol. Pharmacol., May 1, 2006; 69(5): 1615 - 1623. [Abstract] [Full Text] [PDF]